IRVINE, Calif.--(BUSINESS WIRE)--Diality Inc., a medical technology company developing a smart, mobile hemodialysis platform, today announced the hiring of Pamela Wapnick as chief financial officer. She brings to the company more than 30 years of highly diversified financial experience, primarily in the biotech and pharmaceutical industries, as it readies for the commercial launch of its technology in 2023.
Wapnick’s career history includes tenure at Amgen Corp. (NSDQ:AMGN), where she served as both vice president of finance for R&D and vice president and treasurer. In those positions, she led the spending decision process for Amgen’s $3 billion R&D budget, and raised more than $6 billion in financing. She then served as CFO at True North Therapeutics and, later, at Graybug Vision. At True North, she raised $45 million in Series D financing, and led the preparation for an initial public offering prior to the company’s sale to Bioverativ. At Graybug Vision, Wapnick raised $55 million in Series C financing, and completed multiple audits. Most recently, she served as CFO at Capsida Biotherapeutics, where she built several functions of the company from startup to over 100 employees. Wapnick holds a BA in Economics from Wellesley College and an MBA from Columbia University.
Diality is developing a smart hemodialysis platform designed to be as powerful and flexible as in-center treatment, in a small, easy-to-use device. Intended to be safe to operate in any environment, the Diality system’s versatility allows healthcare providers to tailor treatment to each patient’s specific needs regardless of care setting. Its compact footprint and mobility are intended to enable it to be easily integrated into – and transported within – any dialysis setting, be it acute-care hospital, dialysis clinic, transitional care unit, traditional home, or skilled nursing facility.
“Pam is a proven leader with decades of financial and fundraising expertise, both in the private sector and in the capital markets,” said Dr. Osman Khawar, chief executive officer at Diality. “Her extensive experience in the life sciences industry will be invaluable as we look to change the standard of care for dialysis patients.”
Wapnick added, “I was immediately intrigued by Diality’s elegant and innovative approach to mobile hemodialysis and plans to come to market in 2023. I share our team’s dedication to the company’s mission of developing solutions that improve lives impacted by kidney disease.”
About Diality
Diality is a medical technology company developing a smart hemodialysis platform designed to be as powerful and flexible as in-center treatment, in a small, easy-to-use device that’s intended to be safe to operate in any environment, with enough versatility to allow healthcare providers to tailor treatment to each patient’s specific needs. The Diality system’s compact footprint and mobility are intended to enable it to be easily integrated into – and transported within – any dialysis setting, be it acute-care hospital, dialysis clinic, transitional care unit, traditional home, or skilled nursing facility. To learn more, please visit www.diality.com or find us on LinkedIn.
